Impact of prior cancer history on the overall survival of patients newly diagnosed with cancer: A pan-cancer analysis of the SEER database

Huaqiang Zhou, Yan Huang, Zeting Qiu, Hongyun Zhao, Wenfeng Fang, Yunpeng Yang, Yuanyuan Zhao, Xue Hou, Yuxiang Ma, Shaodong Hong, Ting Zhou, Yaxiong Zhang, Li Zhang, Huaqiang Zhou, Yan Huang, Zeting Qiu, Hongyun Zhao, Wenfeng Fang, Yunpeng Yang, Yuanyuan Zhao, Xue Hou, Yuxiang Ma, Shaodong Hong, Ting Zhou, Yaxiong Zhang, Li Zhang

Abstract

The population of cancer survivors with prior cancer is rapidly growing. Whether a prior cancer diagnosis interferes with outcome is unknown. We conducted a pan-cancer analysis to determine the impact of prior cancer history for patients newly diagnosed with cancer. We identified 20 types of primary solid tumors between 2004 and 2008 in the Surveillance, Epidemiology, and End Results database. Demographic and clinicopathologic variables were compared by χ2 test and t-test as appropriate. The propensity score-adjusted Kaplan-Meier method and Cox proportional hazards models were used to evaluate the impact of prior cancer on overall survival (OS). Among 1,557,663 eligible patients, 261,474 (16.79%) had a history of prior cancer. More than 65% of prior cancers were diagnosed within 5 years. We classified 20 cancer sites into two groups (PCI and PCS) according to the different impacts of prior cancer on OS. PCI patients with a prior cancer history, which involved the colon and rectum, bone and soft tissues, melanoma, breast, cervix uteri, corpus and uterus, prostate, urinary bladder, kidney and renal pelvis, eye and orbits, thyroid, had inferior OS. The PCS patients (nasopharynx, esophagus, stomach, liver, gallbladder, pancreas, lung, ovary and brain) with a prior cancer history showed similar OS to that of patients without prior cancer. Our pan-cancer study presents the landscape for the survival impact of prior cancer across 20 cancer types. Compared to the patients without prior cancer, the PCI group had inferior OS, while the PCS group had similar OS. Further studies are still needed.

Keywords: SEER; clinical trial; outcome; pan-cancer; prior cancer; survival.

© 2018 UICC.

References

    1. de Moor JS, Mariotto AB, Parry C, et al. Cancer survivors in the United States: prevalence across the survivorship trajectory and implications for care. Cancer Epidemiol. Biomarkers Prev 2013;22:561-70.
    1. Hayat MJ, Howlader N, Reichman ME, et al. Cancer statistics, trends, and multiple primary cancer analyses from the Surveillance, Epidemiology, and End Results (SEER) Program. Oncologist 2007;12:20-37.
    1. Murphy CC, Gerber DE, Pruitt SL. Prevalence of prior cancer among persons newly diagnosed with cancer: an initial report from the surveillance, epidemiology, and end results program. JAMA Oncol 2017. doi: 10.1001/jamaoncol.2017.3605
    1. Gerber DE, Laccetti AL, Xuan L, et al. Impact of prior cancer on eligibility for lung cancer clinical trials. J Natl Cancer Inst 2014;106:dju302.
    1. Gerber DE, Pruitt SL, Halm EA. Should criteria for inclusion in cancer clinical trials be expanded? J Comp Eff Res 2015;4:289-91.
    1. Laccetti AL, Pruitt SL, Xuan L, et al. Prior cancer does not adversely affect survival in locally advanced lung cancer: a national SEER-medicare analysis. Lung Cancer 2016;98:106-13.
    1. National Cancer Institute. Surveillance, Epidemiology, and End Results (SEER) Program () SEER*Stat Database: Incidence - SEER 18 Regs Research Data + Hurricane Katrina Impacted Louisiana Cases, Nov 2015 Sub (1973-2013 varying) - Linked To County Attributes - Total U.S., 1969-2014 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, Surveillance Systems Branch, released April 2016, based on the November 2015 submission. Available at: , Accessed October 28, 2017.
    1. National Cancer Institute. Surveillance, Epidemiology, and End Results Program. SEER*Stat software version 8.3.4, 2017. Available at: , Accessed October 28, 2017.
    1. Aizer AA, Chen M-H, McCarthy EP, et al. Marital status and survival in patients with cancer. J Clin Oncol 2013;31:3869-76.
    1. Shaikh WR, Weinstock MA, Halpern AC, et al. The characterization and potential impact of melanoma cases with unknown thickness in the United States' Surveillance, Epidemiology, and End Results Program, 1989-2008. Cancer Epidemiol 2013;37:64-70.
    1. Austin PC. An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivariate Behav Res. 2011;46:399-424.
    1. Hosmer DW, Jr., Lemeshow S, May S. Applied survival analysis: regression modeling of time-to-event Data. Hoboken, NJ: John Wiley & Sons, 2011.
    1. Klein JP, Moeschberger ML. Survival analysis: techniques for censored and truncated data. Berlin, Germany: Springer Science & Business Media, 2005.
    1. Laccetti AL, Pruitt SL, Xuan L, et al. Effect of prior cancer on outcomes in advanced lung cancer: implications for clinical trial eligibility and accrual. J Natl Cancer Inst 2015;107:djv002
    1. Verweij PJ, van Houwelingen HC. Time-dependent effects of fixed covariates in Cox regression. Biometrics 1995;51:1550-6.
    1. Dinh KT, Mahal BA, Ziehr DR, et al. Risk of prostate cancer mortality in men with a history of prior cancer. BJU Int 2016;117:E20-E28.
    1. Smyth EC, Tarazona N, Peckitt C, et al. Exclusion of gastrointestinal cancer patients with prior cancer from clinical trials: is this justified? Clin Colorectal Cancer 2016;15:e53-e59.
    1. Sankila R, Hakulinen T. Survival of patients with colorectal carcinoma: effect of prior breast cancer. J Natl Cancer Inst 1998;90:63-5.
    1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin 2017;67:7-30.

Source: PubMed

스폰서 및 공동 작업자

건강 상태

약물 개입

3
구독하다